NCT07393204Active, not recruiting
Italian Real-World Study of Epcoritamab in Relapsed or Refractory DLBCL
Italian Real-world Study on Epcoritamab in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Source: ClinicalTrials.gov · Last updated 6 Feb 2026
Brief summary (registry, in English)
This study describes the effectiveness of epcoritamab outside the clinical trial setting in pts with DLBCL relapsed or refractory after 2 or more previous lines of therapy
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 150 (actual)
- First submitted
- 22 Dec 2025
- Start date
- 10 Dec 2025
- Primary completion date
- 10 Dec 2026
- Lead sponsor
- Andrés José Maria Ferreri
- Diseases
- Diffuse large B-cell lymphoma
- NCT number
- NCT07393204
What you commit to
- Study type: Observational
- Participants enrolled: 150
- From 10 Dec 2025 to the primary completion date, 10 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who received epcoritamab outside the Cnn program (e.g., open access program, compassionate use, off-label, prospective trials).
Age
- Age \< 18 years
Who the study is looking for
- Age ≥ 18 years
- Patients registered in the Cnn program of epcoritamab (between February 19, 2024 and September 25, 2024)
- Received at least one dose of epcoritamab
- Free and voluntary written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Ospedale San Raffaele Coordinator of this site? Confirm its status | Milan | Italy | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.